Oliver Luxxe Assets LLC Has $5.85 Million Holdings in Encompass Health Co. (NYSE:EHC)

Oliver Luxxe Assets LLC increased its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 43.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,553 shares of the company's stock after purchasing an additional 18,407 shares during the period. Encompass Health makes up about 1.0% of Oliver Luxxe Assets LLC's portfolio, making the stock its 29th biggest holding. Oliver Luxxe Assets LLC owned approximately 0.06% of Encompass Health worth $5,852,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. boosted its position in shares of Encompass Health by 387.7% in the third quarter. UMB Bank n.a. now owns 317 shares of the company's stock valued at $31,000 after acquiring an additional 252 shares during the period. Oakworth Capital Inc. bought a new stake in Encompass Health in the 2nd quarter valued at about $40,000. Benjamin F. Edwards & Company Inc. grew its position in shares of Encompass Health by 58.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock worth $46,000 after purchasing an additional 198 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Encompass Health by 31.9% during the first quarter. GAMMA Investing LLC now owns 616 shares of the company's stock worth $51,000 after purchasing an additional 149 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Encompass Health in the second quarter valued at approximately $58,000. 97.25% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the firm's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the transaction, the chief financial officer now owns 136,227 shares of the company's stock, valued at approximately $11,761,839.18. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.10% of the company's stock.

Encompass Health Price Performance

NYSE:EHC traded up $0.29 on Monday, hitting $96.26. The company had a trading volume of 266,923 shares, compared to its average volume of 630,185. The firm has a 50 day moving average of $91.95 and a two-hundred day moving average of $87.44. The stock has a market capitalization of $9.69 billion, a price-to-earnings ratio of 26.02, a PEG ratio of 1.43 and a beta of 0.88. Encompass Health Co. has a 52 week low of $57.55 and a 52 week high of $97.56. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.08.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.10. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The company had revenue of $1.30 billion during the quarter, compared to analysts' expectations of $1.30 billion. During the same period in the prior year, the company earned $0.95 EPS. Encompass Health's revenue was up 9.6% compared to the same quarter last year. On average, research analysts anticipate that Encompass Health Co. will post 4.18 earnings per share for the current year.

Encompass Health announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, July 24th that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to buy up to 5.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.

Encompass Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Tuesday, October 1st. This is a positive change from Encompass Health's previous quarterly dividend of $0.15. Encompass Health's dividend payout ratio (DPR) is 18.38%.

Wall Street Analysts Forecast Growth

EHC has been the topic of a number of recent research reports. Truist Financial raised their price objective on Encompass Health from $104.00 to $108.00 and gave the stock a "buy" rating in a research note on Monday. Stephens reaffirmed an "overweight" rating and issued a $105.00 price target on shares of Encompass Health in a research note on Tuesday, August 6th. UBS Group increased their price objective on shares of Encompass Health from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, September 25th. KeyCorp started coverage on shares of Encompass Health in a research report on Friday. They issued an "overweight" rating and a $115.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Encompass Health in a research report on Wednesday, July 10th. They set an "outperform" rating and a $100.00 price target on the stock. Eight analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $104.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.